Inactive Instrument

Other languages Almirall SA CBOE EUROPE EQUITIES

Equities

ES0157097017

End-of-day quote CBOE EUROPE EQUITIES Other stock markets
- ^EUR	-

May. 13	Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...
May. 13	Almirall confirms full-year targets despite higher first-quarter costs	RE

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ex-dividend day for Cash amount paid with the scrip issue offered as an alternative to the dividend	May. 16	FA
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	May. 13
Las acciones de Almirall suben tras caer el beneficio neto menos de lo previsto	May. 13
Almirall : le titre grimpe après un début d'année 'solide'	May. 13
European shares listless as investors brace for inflation test	May. 13
Transcript : Almirall, S.A., Q1 2024 Earnings Call, May 13, 2024	May. 13
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio	May. 13
Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024	May. 13
Almirall, S.A. Approves Distribution of Dividend	May. 13
Almirall, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 12
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	Mar. 13
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	Mar. 13
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	Feb. 19
Almirall : le titre bondit après un accord avec Novo Nordisk	Feb. 19
Transcript : Almirall, S.A., 2023 Earnings Call, Feb 19, 2024	Feb. 19
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk	Feb. 19
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology	Feb. 19
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk	Feb. 19
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business	Feb. 19
Almirall, S.A. Provides Earnings Guidance for the Year 2024	Feb. 19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Almirall SA CBOE EUROPE EQUITIES

Equities

ES0157097017

Other languages

Filters